Cellectar Biosciences is working on testing a radiosensitive therapy in blood cancers including multiple myeloma. Their product, CLR 131, targets the myeloma tumors by delivering a cytotoxic radioisotope, iodine-131 directly to the tumor cells. Phase I study results showed an overall mean survival rate of 26.2 months for relapsed/refractory myeloma patients (who had received on average 5.8 prior lines of therapy). The drug was given as a one or two-dose treatment as a single agent, given during a 30-minute infusion. These results are promising when compared to recently FDA-approved myeloma treatments.  A Phase II study is now open using CLR 131 and dexamethasone for blood cancer patients including: multiple myeloma (MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therapy for their underlying malignancy. Learn more in this show with Dr. Natalie Callander of the University of Wisconsin School of Medicine.  Thanks to our episode sponsor, GSK.